A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: Post hoc evaluation from a controlled, randomized study

Nephrology Dialysis Transplantation

Volumn 28, Issue 9, 2013, Pages 2383-2392

  Covic, Adrian ^a,i   Passlick Deetjen, Jutta ^b   Kroczak, Miroslaw ^c   Büschges Seraphin, Beatrix ^d   Ghenu, Adrian ^e   Ponce, Pedro ^f   Marzell, Barbara ^g   De Francisco, Angel L M ^h  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Fresenius NephroCare ^*  (Poland)

^d KfH Kuratorium für Hämodialyse   (Germany)

^e Clinical Hospital Târgovi te   (Romania)

^f Almada NMC Centro Médico Nacional   (Portugal)

^g FRESENIUS MEDICAL CARE   (Germany)

^h UNIVERSITY OF CANTABRIA   (Spain)

ⁱ GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Bone markers; Calcium acetate; Fibroblast growth factor 23; Haemodialysis; Magnesium carbonate; Phosphate binder

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; BETA CROSSLAPS; BIOLOGICAL MARKER; CALCIUM ACETATE PLUS MAGNESIUM CARBONATE; FIBROBLAST GROWTH FACTOR 23; MAGNESIUM; OSTEOPROTEGERIN; OSVAREN; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE 1; SEVELAMER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MINERAL METABOLISM; PHOSPHATE BLOOD LEVEL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BONE MARKERS; CALCIUM ACETATE; FIBROBLAST GROWTH FACTOR-23; HAEMODIALYSIS; MAGNESIUM CARBONATE; PHOSPHATE BINDER;

ACETATES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; CALCIUM COMPOUNDS; CHELATING AGENTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MAGNESIUM; MALE; MIDDLE AGED; PARATHYROID HORMONE; POLYAMINES; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS; YOUNG ADULT;

EID: 84884509947     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft203     Document Type: Article

References (50)

1. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617
2. Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506-1523
3. Lezaic V, Tirmenstajn-Jankovic B, Bukvic D et al. Efficacy of hyperphosphatemia control in the progression of chronic renal failure and the prevalence of cardiovascular calcification. Clin Nephrol 2009; 71: 21-29
4. Plantinga LC, Fink NE, Melamed ML et al. Serum phosphate levels and risk of infection in incident dialysis patients. Clin J Am Soc Nephrol 2008; 3: 1398-1406
5. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530
6. Wald R, Sarnak MJ, Tighiouart H et al. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the hemodialysis (HEMO) study. Am J Kidney Dis 2008; 52: 531-540
7. de Francisco AL, Leidig M, Covic AC et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010; 25: 3707-3717
8. Evenepoel P, Meijers B, Viaene L et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 1268-1276
9. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
10. Cozzolino M, Galassi A, Apetrii M et al. What would we like to know, and what do we not know about fibroblast growth factor 23? J Nephrol 2011; 24: 696-706
11. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592
12. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
13. Jean G, Terrat JC, Vanel T et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796
14. Larsson TE. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant 2010; 25: 1376-1381
15. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010; 77: 292-298
16. Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195: 125-131
17. Nakai K, Komaba H, Fukagawa M. New insights into the role of fibroblast growth factor 23 in chronic kidney disease. J Nephrol 2010; 23: 619-625
18. Larsson TE. FGF23 beyond mineral metabolism: a bridge to cardiovascular disease. Clin J Am Soc Nephrol 2011; 6: 2735-2737
19. Seiler S, Reichart B, Roth D et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25: 3983-3989
20. Silver J, Rodriguez M, Slatopolsky E. FGF23 and PTH-double agents at the heart of CKD. Nephrol Dial Transplant 2012; 27: 1715-1720
21. Cancela AL, Oliveira RB, Graciolli FG et al. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron Clin Pract 2011; 117: c74-c82
22. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291
23. Ferreira A, Frazão JM, Monier-Faugere MC et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 2008; 19: 405-412
24. Liu S, Gupta A, Quarles LD. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 2007; 16: 329-335
25. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315
26. Nishi H, Nii-Kono T, Nakanishi S et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract 2005; 101: c94-c99
27. Rodriguez-Ortiz ME, Lopez I, Muñoz-Castaneda JR et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 2012; 23: 1190-1197
28. Wetmore JB, Santos PW, Mahnken JD et al. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J Clin Endocrinol Metab 2011; 96: E57-E64
29. Koizumi M, Komaba H, Nakanishi S et al. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2012; 27: 784-790
30. Couttenye MM, D'Haese PC, Van Hoof VO et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065-1072
31. Ureña P, Hruby M, Ferreira A et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512
32. Jorge C, Gil C, Possante M et al. Bone alkaline phosphatase besides intact parathyroid hormone in hemodialysis patients-any advantage? Nephron Clin Pract 2005; 101: c122-c127
33. Almaden Y, Hernandez A, Torregrosa V et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998; 9: 1845-1852
34. Canalejo A, Canalejo R, Rodriguez ME et al. Development of parathyroid gland hyperplasia without uremia: role of dietary calcium and phosphate. Nephrol Dial Transplant 2010; 25: 1087-1097
35. Barreto DV, Barreto Fde C, de Carvalho AB et al. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract 2008; 110: c273-c283
36. Iwata Y, Wada T, Yokoyama H et al. Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels. Intern Med 2007; 46: 447-452
37. Liu YL, Lin HH, Yu CC et al. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. Ren Fail 2006; 28: 701-707
38. Wesseling-Perry K, Harkins GC, Wang HJ et al. Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols. Pediatr Nephrol 2009; 24: 1355-1361
39. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008; 74: 655-663
40. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203
41. Doumouchtsis KK, Kostakis AI, Doumouchtsis SK et al. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients. J Bone Miner Metab 2008; 26: 66-72
42. Fujimori A, Okada S, Sakai M et al. Relationship between biochemical markers and radial cortical bone changes in hemodialysis patients. Nephron Clin Pract 2011; 118: c375-c379
43. Shidara K, Inaba M, Okuno S et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 2008; 82: 278-287
44. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415
45. Bushinsky DA, Wolbach W, Sessler NE et al. Physicochemical effects of acidosis on bone calcium flux and surface ion composition. J Bone Miner Res 1993; 8: 93-102
46. Bichara M, Mercier O, Borensztein P et al. Acute metabolic acidosis enhances circulating parathyroid hormone, which contributes to the renal response against acidosis in the rat. J Clin Invest 1990; 86: 430-443
47. Navarro-González JF, Mora-Fernández C, Garcia-Pérez J. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 2009; 22: 37-44
48. Kanbay M, Goldsmith D, Uyar ME et al. Magnesium in chronic kidney disease: challenges and opportunities. Blood Purif 2010; 29: 280-292
49. Van Laecke S, Van Biesen W, Vanholder R. Hypomagnesaemia, the kidney and the vessels. Nephrol Dial Transplant 2012; 27: 4003-4010
50. D'Haese PC, Couttenye MM, Lamberts LV et al. Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. Clin Chem 1999; 45: 1548-1556